Company Focused on Responding to FDA for Third-generation Trial NCI to file IND for Sleeping Beauty Manufactured TCR-T Cell Therapies Targeting Neoantigens in 4Q2018 Controlled IL-12 Monotherapy, Combination Studies Advancing Changes to Board of Directors and New Staff Illustrate Company Growth
Scott Tarriff , CEO of Eagle Pharmaceuticals , Elected Lead Director Sir Murray Brennan , M.D., former U.S. Sen. Wyche Fowler to Step Down Paratek Pharmaceuticals CFO Doug Pag á n and Scholar Rock COO Elan Ezickson Nominated to Board Directors BOSTON , Aug.
BOSTON , July 31, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast slide presentation on Wednesday, Aug. 8 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the second quarter
- Executing on clinical and business development with plans to add new Board members and expand management team - Annual meeting of stockholders is Sept. 18 BOSTON , July 26, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next
Phase 1 trial to evaluate Ad-RTS-hIL-12 plus veledimex in combination with nivolumab for treatment of recurrent glioblastoma BOSTON , June 28, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing
BOSTON , June 18, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced the U.S. Food and Drug Administration ( FDA ) placed on clinical hold a Phase 1 trial to evaluate CD19-specific CAR-T therapies manufactured under point-of-care and requested additional information in
- Ad-RTS-hIL-12 plus veledimex recruits T cells into breast and brain cancers - Median overall survival reaches 12.7 months in patients with recurrent glioblastoma in 20mg veledimex cohort who received Controlled IL-12 as a single agent - Over expression of immune checkpoint biomarkers demonstrated
- Data from biopsies shows Ad-RTS-hIL-12 plus veledimex recruits killer T cells into breast and brain cancers - IL-12 continues to demonstrate activity as a single-agent therapy, prolongs survival in patients with recurrent glioblastoma - Results further support development of
-Expanding Controlled IL-12 platform to explore additional tumor types -Cash runway extended to 2Q 2019 with changes to Controlled IL-12 development plans -ASCO poster to detail IL-12 data in breast cancer, glioblastoma, highlight potential for combination with checkpoint inhibitors
BOSTON , May 02, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, May 10 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the first quarter ended
